JP6346622B2 - ナトリウムチャネルの調節剤としてのアミド - Google Patents
ナトリウムチャネルの調節剤としてのアミド Download PDFInfo
- Publication number
- JP6346622B2 JP6346622B2 JP2015556113A JP2015556113A JP6346622B2 JP 6346622 B2 JP6346622 B2 JP 6346622B2 JP 2015556113 A JP2015556113 A JP 2015556113A JP 2015556113 A JP2015556113 A JP 2015556113A JP 6346622 B2 JP6346622 B2 JP 6346622B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- another embodiment
- benzamido
- pain
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*(C)(C(c(c(*)cc(C1=*C1)c1)c1Oc1ccc(*)cc1)=O)C(C=C1)=CC(CC2C(*)=C2)*=C1C(OC)=* Chemical compound C*(C)(C(c(c(*)cc(C1=*C1)c1)c1Oc1ccc(*)cc1)=O)C(C=C1)=CC(CC2C(*)=C2)*=C1C(OC)=* 0.000 description 5
- DTKQCLRHNWDXBG-UHFFFAOYSA-N C=Nc(ccc(F)c1)c1Cl Chemical compound C=Nc(ccc(F)c1)c1Cl DTKQCLRHNWDXBG-UHFFFAOYSA-N 0.000 description 1
- LXWFHMREWLOKLM-UHFFFAOYSA-N CC(C)CCOc(cc1)ccc1N Chemical compound CC(C)CCOc(cc1)ccc1N LXWFHMREWLOKLM-UHFFFAOYSA-N 0.000 description 1
- MDYXLRQCQPAWEX-UHFFFAOYSA-N CN(C)c(ccc(F)c1)c1F Chemical compound CN(C)c(ccc(F)c1)c1F MDYXLRQCQPAWEX-UHFFFAOYSA-N 0.000 description 1
- HKWSUHGMFVMEIM-UHFFFAOYSA-N COc(cc1)cc(Cl)c1Oc(ccc(C(F)(F)F)c1)c1C(Nc1ccc(C(O)=O)nc1)=O Chemical compound COc(cc1)cc(Cl)c1Oc(ccc(C(F)(F)F)c1)c1C(Nc1ccc(C(O)=O)nc1)=O HKWSUHGMFVMEIM-UHFFFAOYSA-N 0.000 description 1
- VQNBFIKXEZCCAT-UHFFFAOYSA-N COc(cc1)cc(OC)c1N=C Chemical compound COc(cc1)cc(OC)c1N=C VQNBFIKXEZCCAT-UHFFFAOYSA-N 0.000 description 1
- SYSZENVIJHPFNL-UHFFFAOYSA-N COc(cc1)ccc1I Chemical compound COc(cc1)ccc1I SYSZENVIJHPFNL-UHFFFAOYSA-N 0.000 description 1
- CXNVOWPRHWWCQR-UHFFFAOYSA-N Cc(cc(cc1)Cl)c1N Chemical compound Cc(cc(cc1)Cl)c1N CXNVOWPRHWWCQR-UHFFFAOYSA-N 0.000 description 1
- JWQUBAUGVPTBAE-UHFFFAOYSA-N Cc(cc(cc1)F)c1NC Chemical compound Cc(cc(cc1)F)c1NC JWQUBAUGVPTBAE-UHFFFAOYSA-N 0.000 description 1
- MIRMWZQQRUXCNH-UHFFFAOYSA-N Cc(cc(cc1)F)c1Oc(cc(c(Cl)c1)Cl)c1C(Nc1ccc(C(O)=O)nc1)=O Chemical compound Cc(cc(cc1)F)c1Oc(cc(c(Cl)c1)Cl)c1C(Nc1ccc(C(O)=O)nc1)=O MIRMWZQQRUXCNH-UHFFFAOYSA-N 0.000 description 1
- ZWSJDCCDISWMKX-UHFFFAOYSA-N Cc(cc(cc1)F)c1Oc1ccc(C(F)(F)F)cc1C(Nc(cc1)ccc1C(O)=O)=O Chemical compound Cc(cc(cc1)F)c1Oc1ccc(C(F)(F)F)cc1C(Nc(cc1)ccc1C(O)=O)=O ZWSJDCCDISWMKX-UHFFFAOYSA-N 0.000 description 1
- AKOGFIZZLZJNQH-UHFFFAOYSA-N Cc(cc(cc1)F)c1Oc1ccc(C(F)(F)F)cc1C(Nc1ccc(C(O)=O)nc1)=O Chemical compound Cc(cc(cc1)F)c1Oc1ccc(C(F)(F)F)cc1C(Nc1ccc(C(O)=O)nc1)=O AKOGFIZZLZJNQH-UHFFFAOYSA-N 0.000 description 1
- CXTIUQIZWCABPV-UHFFFAOYSA-N Cc(ccc(F)c1)c1OC Chemical compound Cc(ccc(F)c1)c1OC CXTIUQIZWCABPV-UHFFFAOYSA-N 0.000 description 1
- RRSGOCVSLFHGAX-UHFFFAOYSA-N Cc1cc(Cl)ccc1Oc1ccc(C(F)(F)F)cc1C(Nc1ccc(C(O)=O)nc1)=O Chemical compound Cc1cc(Cl)ccc1Oc1ccc(C(F)(F)F)cc1C(Nc1ccc(C(O)=O)nc1)=O RRSGOCVSLFHGAX-UHFFFAOYSA-N 0.000 description 1
- RTUDBROGOZBBIC-UHFFFAOYSA-N FC(Oc(cc1)ccc1I)(F)F Chemical compound FC(Oc(cc1)ccc1I)(F)F RTUDBROGOZBBIC-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N Nc(cc1)ccc1F Chemical compound Nc(cc1)ccc1F KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- TWHKITDGPNXHCU-UHFFFAOYSA-N OC(c(cc1)ccc1NC(c(cc(c(Cl)c1)Cl)c1Oc(cccc1)c1OC(F)F)=O)=O Chemical compound OC(c(cc1)ccc1NC(c(cc(c(Cl)c1)Cl)c1Oc(cccc1)c1OC(F)F)=O)=O TWHKITDGPNXHCU-UHFFFAOYSA-N 0.000 description 1
- YNBSBKHHRRBEHX-UHFFFAOYSA-N OC(c(nc1)ccc1NC(c(c(C(F)(F)F)cc(C(F)(F)F)c1)c1Oc(cc1)ccc1F)=O)=O Chemical compound OC(c(nc1)ccc1NC(c(c(C(F)(F)F)cc(C(F)(F)F)c1)c1Oc(cc1)ccc1F)=O)=O YNBSBKHHRRBEHX-UHFFFAOYSA-N 0.000 description 1
- IUYUKZBMJINCLE-UHFFFAOYSA-N OC(c(nc1)ccc1NC(c(ccc(C(F)(F)F)c1)c1Oc(cc1)ccc1F)=O)=O Chemical compound OC(c(nc1)ccc1NC(c(ccc(C(F)(F)F)c1)c1Oc(cc1)ccc1F)=O)=O IUYUKZBMJINCLE-UHFFFAOYSA-N 0.000 description 1
- ZJDFLPLEPVWDIP-UHFFFAOYSA-N OC(c(nc1)ccc1NC(c1cc(C(F)(F)F)ccc1Oc(ccc(F)c1)c1Cl)=O)=O Chemical compound OC(c(nc1)ccc1NC(c1cc(C(F)(F)F)ccc1Oc(ccc(F)c1)c1Cl)=O)=O ZJDFLPLEPVWDIP-UHFFFAOYSA-N 0.000 description 1
- QAJFPIFCJNLXPC-UHFFFAOYSA-N OC(c(nc1)ccc1NC(c1cc(C(F)(F)F)ccc1Oc1ccccc1)=O)=O Chemical compound OC(c(nc1)ccc1NC(c1cc(C(F)(F)F)ccc1Oc1ccccc1)=O)=O QAJFPIFCJNLXPC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759062P | 2013-01-31 | 2013-01-31 | |
| US61/759,062 | 2013-01-31 | ||
| PCT/US2014/013667 WO2014120820A1 (en) | 2013-01-31 | 2014-01-29 | Amides as modulators of sodium channels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016508500A JP2016508500A (ja) | 2016-03-22 |
| JP2016508500A5 JP2016508500A5 (https=) | 2017-03-09 |
| JP6346622B2 true JP6346622B2 (ja) | 2018-06-20 |
Family
ID=50114569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015556113A Active JP6346622B2 (ja) | 2013-01-31 | 2014-01-29 | ナトリウムチャネルの調節剤としてのアミド |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9108903B2 (https=) |
| EP (1) | EP2951155B1 (https=) |
| JP (1) | JP6346622B2 (https=) |
| KR (1) | KR102226588B1 (https=) |
| CN (1) | CN104968647B (https=) |
| AR (1) | AR094668A1 (https=) |
| AU (1) | AU2014212431B2 (https=) |
| BR (1) | BR112015018284B1 (https=) |
| CA (1) | CA2898653C (https=) |
| IL (1) | IL240196B (https=) |
| MX (1) | MX359882B (https=) |
| RU (1) | RU2658920C2 (https=) |
| SG (1) | SG11201505954RA (https=) |
| TW (1) | TWI659945B (https=) |
| WO (1) | WO2014120820A1 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102295748B1 (ko) | 2013-01-31 | 2021-09-01 | 버텍스 파마슈티칼스 인코포레이티드 | 나트륨 채널의 조절제로서의 피리돈 아미드 |
| CN105073738B (zh) | 2013-01-31 | 2018-01-05 | 沃泰克斯药物股份有限公司 | 作为钠通道调节剂的喹啉及喹喔啉酰胺类 |
| ES2654393T3 (es) | 2013-07-19 | 2018-02-13 | Vertex Pharmaceuticals Incorporated | Sulfonamidas como moduladores de los canales de sodio |
| LT3080134T (lt) | 2013-12-13 | 2018-11-12 | Vertex Pharmaceuticals Incorporated | Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai |
| US11358977B2 (en) | 2017-05-16 | 2022-06-14 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| SG11202000230VA (en) | 2017-07-11 | 2020-02-27 | Vertex Pharma | Carboxamides as modulators of sodium channels |
| WO2019157505A1 (en) | 2018-02-12 | 2019-08-15 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
| EP3873893A1 (en) | 2018-11-02 | 2021-09-08 | Merck Sharp & Dohme Corp. | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
| WO2020092187A1 (en) | 2018-11-02 | 2020-05-07 | Merck Sharp & Dohme Corp. | 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors |
| CA3125244A1 (en) * | 2019-01-04 | 2020-07-09 | Jiangsu Hengrui Medicine Co., Ltd. | 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| US12441703B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| CN112996776B (zh) * | 2019-02-20 | 2024-03-15 | 福建盛迪医药有限公司 | 6-氧代-1,6-二氢哒嗪类前药衍生物、其制备方法及其在医药上的应用 |
| WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
| WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
| GEP20247688B (en) * | 2019-09-12 | 2024-11-11 | Orion Corp | Pyridine oxynitride, preparation method therefor and use thereof |
| CA3164134A1 (en) * | 2019-12-06 | 2021-06-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
| CN114437062B (zh) * | 2020-04-30 | 2024-05-17 | 成都海博为药业有限公司 | 一种可作为钠通道调节剂的化合物及其用途 |
| GEP20257750B (en) | 2020-06-17 | 2025-03-25 | Merck Sharp & Dohme Llc | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors |
| JP2023530319A (ja) | 2020-06-17 | 2023-07-14 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｎａｖ１．８阻害剤としての２－オキソ－オキサゾリジン－５－カルボキサミド |
| CN113880771B (zh) * | 2020-07-03 | 2023-09-19 | 福建盛迪医药有限公司 | 一种选择性Nav抑制剂的结晶形式及其制备方法 |
| CN114031518B (zh) * | 2020-12-08 | 2023-08-18 | 成都海博为药业有限公司 | 一种苄胺或苄醇衍生物及其用途 |
| CN112225695B (zh) * | 2020-12-15 | 2021-03-02 | 上海济煜医药科技有限公司 | 一种氮氧化合物及其制备方法和用途 |
| BR112023018348A2 (pt) * | 2021-03-11 | 2023-12-05 | Jiangxi Jemincare Group Co Ltd | Forma de cristal de composto de óxido de nitrogênio e piridina e uso da mesma |
| EP4334293A1 (en) | 2021-05-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors |
| CA3221788A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| JP2024520646A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド類似体 |
| JP2024520643A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの調節因子としてのヒドロキシ及び（ハロ）アルコキシ置換テトラヒドロフラン |
| WO2022256676A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| SI4347031T1 (sl) | 2021-06-04 | 2026-01-30 | Vertex Pharmaceuticals Incorporated | N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov |
| MA64856B1 (fr) | 2021-06-04 | 2026-02-27 | Vertex Pharmaceuticals Incorporated | Formes de dosage solides et regimens de dosage comprenant le [[3-(3,4-difluoro-2-méthoxy-phényl)-4,5-diméthyl-5-(trifluorométhyl) tétrahydrofuranne-2-carbonyl]amino]pyridine-2-carboxamide |
| JP2025513452A (ja) | 2022-04-22 | 2025-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛の治療のためのヘテロアリール化合物 |
| GEAP202516634A (en) | 2022-04-22 | 2025-02-25 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
| UY40234A (es) | 2022-04-22 | 2023-11-15 | Vertex Pharma | Compuestos heteroarilo para el tratamiento del dolor |
| AU2023257313A1 (en) | 2022-04-22 | 2024-10-31 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| IL316433A (en) | 2022-04-25 | 2024-12-01 | Siteone Therapeutics Inc | Bicyclic heterocyclic amide inhibitors of NA v1.8 for the treatment of pain |
| AU2023391870A1 (en) | 2022-12-06 | 2025-06-05 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| WO2024153856A1 (en) * | 2023-01-18 | 2024-07-25 | Orion Corporation | Process for the preparation of 3-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)pyridine 1-oxide |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025122953A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens and formulations of suzetrigine for use in the treatment of acute and chronic pain |
| WO2025160286A1 (en) | 2024-01-24 | 2025-07-31 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2511231A (en) * | 1949-03-26 | 1950-06-13 | Eastman Kodak Co | 1-cyanophenyl-3-acylamino-5-pyrazolone couplers for color photography |
| CA2648202A1 (en) | 2006-04-11 | 2007-10-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
| AU2008310661A1 (en) | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
| CN101883760A (zh) | 2007-10-11 | 2010-11-10 | 沃泰克斯药物股份有限公司 | 用作电压-门控钠通道抑制剂的杂芳基酰胺类 |
| CA2702101A1 (en) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
| EP2435407B1 (en) * | 2009-05-29 | 2019-12-25 | RaQualia Pharma Inc. | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers |
-
2014
- 2014-01-29 AU AU2014212431A patent/AU2014212431B2/en active Active
- 2014-01-29 BR BR112015018284-4A patent/BR112015018284B1/pt not_active IP Right Cessation
- 2014-01-29 CA CA2898653A patent/CA2898653C/en active Active
- 2014-01-29 KR KR1020157023600A patent/KR102226588B1/ko not_active Expired - Fee Related
- 2014-01-29 EP EP14704981.1A patent/EP2951155B1/en active Active
- 2014-01-29 RU RU2015136779A patent/RU2658920C2/ru active
- 2014-01-29 JP JP2015556113A patent/JP6346622B2/ja active Active
- 2014-01-29 WO PCT/US2014/013667 patent/WO2014120820A1/en not_active Ceased
- 2014-01-29 AR ARP140100282A patent/AR094668A1/es unknown
- 2014-01-29 US US14/167,741 patent/US9108903B2/en active Active
- 2014-01-29 SG SG11201505954RA patent/SG11201505954RA/en unknown
- 2014-01-29 MX MX2015009591A patent/MX359882B/es active IP Right Grant
- 2014-01-29 CN CN201480006878.4A patent/CN104968647B/zh active Active
- 2014-01-29 TW TW103103690A patent/TWI659945B/zh not_active IP Right Cessation
-
2015
- 2015-07-27 US US14/809,841 patent/US9421196B2/en active Active
- 2015-07-28 IL IL240196A patent/IL240196B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| TW201443005A (zh) | 2014-11-16 |
| NZ710293A (en) | 2020-09-25 |
| MX2015009591A (es) | 2016-04-15 |
| KR20150118964A (ko) | 2015-10-23 |
| SG11201505954RA (en) | 2015-08-28 |
| IL240196B (en) | 2019-08-29 |
| HK1217692A1 (en) | 2017-01-20 |
| CN104968647B (zh) | 2018-01-26 |
| US9421196B2 (en) | 2016-08-23 |
| BR112015018284A2 (pt) | 2017-07-18 |
| US20140221435A1 (en) | 2014-08-07 |
| BR112015018284B1 (pt) | 2023-03-07 |
| WO2014120820A9 (en) | 2015-07-02 |
| AR094668A1 (es) | 2015-08-19 |
| AU2014212431A1 (en) | 2015-08-06 |
| CA2898653C (en) | 2021-09-28 |
| RU2015136779A (ru) | 2017-03-07 |
| CN104968647A (zh) | 2015-10-07 |
| US9108903B2 (en) | 2015-08-18 |
| EP2951155B1 (en) | 2019-06-19 |
| RU2658920C2 (ru) | 2018-06-26 |
| EP2951155A1 (en) | 2015-12-09 |
| US20150328196A1 (en) | 2015-11-19 |
| TWI659945B (zh) | 2019-05-21 |
| KR102226588B1 (ko) | 2021-03-11 |
| JP2016508500A (ja) | 2016-03-22 |
| CA2898653A1 (en) | 2014-08-07 |
| AU2014212431B2 (en) | 2018-04-05 |
| WO2014120820A1 (en) | 2014-08-07 |
| MX359882B (es) | 2018-10-15 |
| IL240196A0 (en) | 2015-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6346622B2 (ja) | ナトリウムチャネルの調節剤としてのアミド | |
| JP6362623B2 (ja) | ナトリウムチャネルの調節剤としてのキノリンおよびキノキサリンアミド | |
| JP6389194B2 (ja) | ナトリウムチャネルの調節剤としてのピリドンアミド | |
| JP6337109B2 (ja) | ナトリウムチャネルの調節剤としてのスルホンアミド | |
| JP6463580B2 (ja) | ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ | |
| HK1217692B (en) | Amides as modulators of sodium channels | |
| HK1217691B (en) | Quinoline and quinazoline amides as modulators of sodium channels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170130 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170130 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171109 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180316 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180501 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180525 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6346622 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |